CD274 and cancer: Use of CPS positivity to identify those cancers who may benefit from PD1/PDL1 blockade would therefore seem appropriate, however other studies have reported responses in PDL1 negative tumours, including Checkmate-358 which used the IHC 28-8 pharmDx assay [18].